Septerna’s $150M infusion will help prove whether it’s got the right pill for hypoparathyroidism

A hefty Se­ries B will bankroll Septer­na’s first clin­i­cal tri­al, which will be a key test of whether the com­pa­ny’s pill will be the first oral op­tion to suc­cess­ful­ly treat hy­poparathy­roidism.

With $150 mil­lion from more than 15 in­vestors, in­clud­ing many mar­quee firms in biotech, Septer­na will study its oral small mol­e­cule in hu­mans and po­ten­tial­ly bring an­oth­er one of its pro­grams in­to the clin­ic, CEO Jef­frey Fin­er told End­points News ahead of Tues­day’s fi­nanc­ing dis­clo­sure.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN